Abstract: There is provided a detection circuit, a display panel and a detection method. The detection circuit includes: a conversion circuit configured to acquire a photoelectric sensing signal in real time and convert the acquired photoelectric sensing signal into a luminance value; a storage circuit configured to store N luminance values from the conversion circuit on a first input first output basis; a discrimination circuit connected to the storage circuit and configured to determine whether at least two of the N luminance values meet a preset condition; and an output circuit connected to the discrimination circuit and the storage circuit, and configured to output a preset default luminance value in response to the at least two luminance values meeting the preset condition and output at least one of the N luminance values in response to the at least two luminance values not meeting the preset condition.

Abstract: Disclosed are a prefabricated energy pile, a construction method and a heat pump heat exchange system. The energy pile includes a pile body and a heat exchange pipeline. The pile body includes a stainless steel pipe, a metal lining pipe extending within the stainless steel pipe and a concrete pipe between the metal lining pipe and the stainless steel pipe. A heat conductor between the stainless steel pipe and the metal lining pipe is in contact connection with the stainless steel pipe and the metal lining pipe. The heat exchange pipeline includes a first pipe section and a second pipe section in communication with each other, through which a heat exchange medium flows in turn. Tops of the first pipe section and the second pipe section protrude upward out of the energy pile. The second pipe section is in contact connection with the metal lining pipe.

Abstract: Disclosed are a prefabricated energy pile, a construction method and a heat pump heat exchange system. The energy pile includes a pile body and a heat exchange pipeline. The pile body includes a stainless steel pipe, a metal lining pipe extending within the stainless steel pipe and a concrete pipe between the metal lining pipe and the stainless steel pipe. A heat conductor between the stainless steel pipe and the metal lining pipe is in contact connection with the stainless steel pipe and the metal lining pipe. The heat exchange pipeline includes a first pipe section and a second pipe section in communication with each other, through which a heat exchange medium flows in turn. Tops of the first pipe section and the second pipe section protrude upward out of the energy pile. The second pipe section is in contact connection with the metal lining pipe.

Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody or fusion protein thereof. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody fusion protein thereof.

Abstract: A spiral magnetic fluid composite sealing structure of a roller bit comprising a cone leg and a roller, wherein the roller and the cone leg are in rotatable connection in a fitting manner through a roller inner hole and a cone leg shaft journal, a sealing groove is formed in an opening end of the roller inner hole, and a spiral magnetic fluid sealing assembly is arranged in the sealing groove. Through the arrangement of the spiral magnetic fluid sealing assembly, a spiral sand discharging effect is realized, compared with a passive sealing mode, the sealing performance is greatly improved by active sand discharging mode, and the service life of sealing is significantly prolonged; a slurry sealing effect of magnetic fluid seals is realized, resulting the sealing gap is tightly sealed under the magnetic action; in addition, the automatic compensation function of magnetic fluid can also be realized.

Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody.

Abstract: This invention relates to factor B inhibitors or nucleic acid molecules encoding thereof and selective inhibition of the alternative pathway (AP) of the complement system using said factor B inhibitors or nucleic acid molecules encoding thereof or compositions thereof. The invention also provides methods of treating an AP complement-mediated disease or AP complement-mediated disorder in a subject by administering a therapeutically effective amount of the factor B inhibitor or nucleic acid molecules encoding thereof or composition thereof.

Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody.

Abstract: This invention relates to selective inhibition of the alternative pathway (AP) of the complement system using an anti-factor D antibody. Specifically, the invention relates to methods of treating an AP-mediated disease or AP-mediated disorder in an individual by contacting the individual with an anti-factor D antibody.

Abstract: This invention relates to selective inhibition of the alternative pathway (AP) of the complement system using an anti-factor D antibody. Specifically, the invention relates to methods of treating an AP-mediated disease or AP-mediated disorder in an individual by contacting the individual with an anti-factor D antibody.

Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody or fusion protein thereof. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody fusion protein thereof.

Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody.

Abstract: This invention relates to inhibition of the complement signaling using an anti-C5a antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5a antibody.

Abstract: This invention relates to inhibition of the complement signaling using an anti-C5a antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5a antibody.

Abstract: A recombinant vector having an expression cassette comprising a modified human factor H (hfH) gene is provided, wherein said hfH gene encodes a hfH protein variant comprising SCR1-4, 19-20, and one or more of SCR7, SCR17 and/or SCR18. Also provided are pharmaceutical compositions containing this vector and uses therefor in treating AMD and/or other complement associated diseases.

Abstract: Provided herein is a recombinant viral vector having packaged therein an expression cassette comprising an engineered complement regulator factor H (fH), wherein the gene encodes a hfH protein variant comprising short consensus repeats (SCRs) 1-4, 6-8, and 17-20. Pharmaceutical compositions containing this vector and plasmids comprising nucleic acid sequences that encode the fH protein variant are also provided.

Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody.

Abstract: This invention relates to inhibition of the complement signaling using an anti-C5a antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5a antibody.

Abstract: This invention relates to selective inhibition of the alternative pathway (AP) of the complement system using an anti-factor D antibody. Specifically, the invention relates to methods of treating an AP-mediated disease or AP-mediated disorder in an individual by contacting the individual with an anti-factor D antibody.

Abstract: A recombinant vector having an expression cassette comprising a modified human factor H (hfH) gene is provided, wherein said hfH gene encodes a hfH protein variant comprising SCR1-4, 19-20, and one or more of SCR7, SCR17 and/or SCR18. Also provided are pharmaceutical compositions containing this vector and uses therefor in treating AMD and/or other complement associated diseases.